戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  13 study participants developed antibody to hepatitis B core antigen (10 vaccine responders, 3 nonre
2 gen-positive patients and in those with anti-hepatitis B core antigen alone compared with HBV-uninfec
3 re likely to be HCV and antibody reacting to hepatitis B core antigen+, and less likely to have diabe
4 February 2003 were tested for anti-HIV, anti-hepatitis B core antigen, and anti-HCV and were intervie
5 en (hepatitis B surface antigen, antibody to hepatitis B core antigen, and antibody to hepatitis B su
6 ce and risk factors for isolated antibody to hepatitis B core antigen (anti-HBc) and occult hepatitis
7 HBs carriers than in donors with antibody to hepatitis B core antigen (anti-HBc) only.
8 s who test positive for isolated antibody to hepatitis B core antigen (anti-HBc) should be vaccinated
9 titis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and anti-HBs level.
10 titis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and antibody to hep
11 odies to HBsAg (anti-HBs), antibodies to the hepatitis B core antigen (anti-HBc), HBV DNA, and antibo
12 s 6 years of age were tested for antibody to hepatitis B core antigen (anti-HBc), hepatitis B surface
13 rsons age 6 years and older for: antibody to hepatitis B core antigen (anti-HBc), indicative of previ
14  in vaccinated than unvaccinated antibody to hepatitis B core antigen (anti-HBc)-negative subjects (0
15 recurrent hepatitis C in an antibody against hepatitis B core antigen (anti-HBc)-positive LT recipien
16 urface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive patients af
17 e antigen (HBsAg) and for antibodies against hepatitis B core antigen (anti-HBc).
18 B surface antigen (HBsAg), and antibodies to hepatitis B core antigen (anti-HBc).
19 surface antigen (HBsAg) but with antibody to hepatitis B core antigen (anti-HBc).
20 rafts from donors who have antibodies to the hepatitis B core antigen (anti-HBc+).
21 tis B surface antigen (HBsAg), antibodies to hepatitis B core antigen, antibodies to HBsAg, and antib
22 emonstrated the disappearance of cytoplasmic hepatitis B core antigen from both tissues after IL-12 t
23 d HB, 82 (3%) had isolated total antibody to hepatitis B core antigen (HBcAb), and 64 (3%) had chroni
24 rus like particle (VLP) carrier based on the hepatitis B core antigen (HBcAg) that displays the ZIKV
25  molecular target of these antibodies is the hepatitis B core antigen (HBcAg); that these anti-bodies
26 atitis B surface antigen and the antibody to hepatitis B core antigen in serum.
27 %-19%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%-7
28  0.14-0.32) versus patients with antibody to hepatitis B core antigen only.
29 th the protein vaccine CV-1866, based on the hepatitis B core antigen particle, induced strong humora
30                                              Hepatitis B core antigen-specific T cell proliferation c
31 ines were determined by specific ELISAs, and hepatitis B core antigen-specific T cell response by a p
32 were normal, hepatitis B surface antigen and hepatitis B core antigen staining of biopsies was negati
33 xpression of hepatitis B surface antigen and hepatitis B core antigen was detected in approximately 2
34 s I and II, human immunodeficiency virus, or hepatitis B core antigen was highly associated with HCV

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。